Literature DB >> 24838431

Severe hypomagnesaemia causing reversible cerebellopathy.

M G E Te Riele1, A Verrips.   

Abstract

Hypomagnesaemia is common among hospitalised patients and is often under-recognised. Chronic alcohol abuse and alcohol withdrawal are known causes for severe hypomagnesaemia. Hypomagnesaemia can present with cardiac arrhythmias, seizures and other neurological symptoms, among which ataxia. We present a 57-year-old man with a history of chronic alcohol abuse who developed a subacute cerebellar syndrome with hypertension after alcohol withdrawal. A severe hypomagnesaemia of 0.19 mmol/L (normal values 0.70-1.10) was found. MRI showed diffuse, T2 hyperintense lesions in and swelling of the cerebellum. Symptoms, hypertension and MRI abnormalities significantly improved rapidly after intravenous magnesium supplementation. Hypomagnesaemia can cause a subacute, cerebellar syndrome and hypertension. Symptoms, hypertension and MRI abnormalities can be reversed with rapid magnesium supplementation. MRI abnormalities are similar to those caused by vascular endothelial dysregulation seen in posterior reversible encephalopathy syndrome (PRES). A similar case was recently described. We confirm that magnesium is likely to be involved in the pathophysiology of PRES.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24838431     DOI: 10.1007/s12311-014-0567-2

Source DB:  PubMed          Journal:  Cerebellum        ISSN: 1473-4222            Impact factor:   3.847


  10 in total

1.  Frequency of hypomagnesemia and hypermagnesemia. Requested vs routine.

Authors:  R Whang; K W Ryder
Journal:  JAMA       Date:  1990-06-13       Impact factor: 56.272

Review 2.  Physiological and pathophysiological role of magnesium in the cardiovascular system: implications in hypertension.

Authors:  P Laurant; R M Touyz
Journal:  J Hypertens       Date:  2000-09       Impact factor: 4.844

3.  [Blood plasma potassium, sodium and magnesium levels in chronic alcoholism during alcohol withdrawal].

Authors:  Virginija Stasiukyniene
Journal:  Medicina (Kaunas)       Date:  2002       Impact factor: 2.430

4.  Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings.

Authors:  Jennifer E Fugate; Daniel O Claassen; Harry J Cloft; David F Kallmes; Osman S Kozak; Alejandro A Rabinstein
Journal:  Mayo Clin Proc       Date:  2010-05       Impact factor: 7.616

Review 5.  How should hypomagnesaemia be investigated and treated?

Authors:  John Ayuk; Neil J L Gittoes
Journal:  Clin Endocrinol (Oxf)       Date:  2011-12       Impact factor: 3.478

6.  Severe hypomagnesemia associated with reversible subacute ataxia and cerebellar hyperintensities on MRI.

Authors:  Mark I Boulos; Ashkan Shoamanesh; Richard I Aviv; David J Gladstone; Richard H Swartz
Journal:  Neurologist       Date:  2012-07       Impact factor: 1.398

Review 7.  Magnesium for alcohol withdrawal.

Authors:  Michael Sarai; Aaron M Tejani; Alice Hill Wah Chan; I Fan Kuo; Juliana Li
Journal:  Cochrane Database Syst Rev       Date:  2013-06-05

8.  Focal cerebral deficits in severe hypomagnesemia.

Authors:  C R Leicher; A G Mezoff; J S Hyams
Journal:  Pediatr Neurol       Date:  1991 Sep-Oct       Impact factor: 3.372

Review 9.  Neuroimaging in posterior reversible encephalopathy syndrome.

Authors:  C Lamy; C Oppenheim; J F Méder; J L Mas
Journal:  J Neuroimaging       Date:  2004-04       Impact factor: 2.486

10.  Renal tubular dysfunction in chronic alcohol abuse--effects of abstinence.

Authors:  S De Marchi; E Cecchin; A Basile; A Bertotti; R Nardini; E Bartoli
Journal:  N Engl J Med       Date:  1993-12-23       Impact factor: 91.245

  10 in total
  9 in total

1.  Cerebellar Bottom-of-Fissure Dysplasia-a Novel Cerebellar Gray Matter Neuroimaging Pattern.

Authors:  Andrea Poretti; Andrea Capone; Anette Hackenberg; Ingeborg Kraegeloh-Mann; Gerhard Kurlemann; Guido Laube; Joachim Pietz; Mareike Schimmel; Wolfram Schwindt; Ianina Scheer; Eugen Boltshauser
Journal:  Cerebellum       Date:  2016-12       Impact factor: 3.847

Review 2.  Anti-Angiogenic Tyrosine Kinase Inhibitors and Reversible Posterior Leukoencephalopathy Syndrome: Could Hypomagnesaemia Be the Trigger?

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2017-05       Impact factor: 5.606

3.  Maternal magnesium therapy, neonatal serum magnesium concentration and immediate neonatal outcomes.

Authors:  D Narasimhulu; A Brown; N M Egbert; M Rojas; S Haberman; A Bhutada; H Minkoff; S Rastogi
Journal:  J Perinatol       Date:  2017-10-05       Impact factor: 2.521

4.  Can diabetic ketoacidosis (DKA) precipitate posterior reversible encephalopathy syndrome (PRES)?

Authors:  Ravi Sharma; Prateek Sharma; Varidh Katiyar; Zainab Vora; Hitesh Gurjar
Journal:  Childs Nerv Syst       Date:  2018-04-20       Impact factor: 1.475

5.  Dilemma in the emergency setting: hypomagnesemia mimicking acute stroke.

Authors:  María Rico; Laura Martinez-Rodriguez; Davinia Larrosa-Campo; Sergio Calleja
Journal:  Int Med Case Rep J       Date:  2016-06-11

6.  Posterior Reversible Encephalopathy Syndrome due to Hypomagnesemia: A Case Report and Literature Review.

Authors:  Mohamad Almoussa; Angelika Goertzen; Stephan Brauckmann; Barbara Fauser; Christoph W Zimmermann
Journal:  Case Rep Med       Date:  2018-11-29

7.  Posterior Reversible Encephalopathy Syndrome Induced by Hypomagnesemia due to Clostridium Difficile in a Patient with Kidney Transplant.

Authors:  Mohammad Alsultan; Qussai Hassan
Journal:  Case Rep Neurol       Date:  2021-10-22

8.  Imaging findings in TRPM6-Related hypomagnesemia with secondary hypocalcemia.

Authors:  Prateek Malik; Sayli Umakant Bidkar; Sangeetha Yoganathan; Sarah Mathai; Sumita Danda; Beena Koshy
Journal:  Ann Indian Acad Neurol       Date:  2021-04-28       Impact factor: 1.383

9.  A case report of posterior reversible encephalopathy syndrome in a patient receiving gemcitabine and cisplatin.

Authors:  Hannah Cherniawsky; Neesha Merchant; Micheal Sawyer; Maria Ho
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.